Skip to main content

EXPLORACION DE NUEVAS MOLECULAS DIRECCIONADORAS EFICIENTES PARA LA LIBERACION DE ANTIMALARICOS MEDIANTE NANOVECTORES

BIO2011-25039

•
Funding agency name Ministerio de Ciencia e Innovación
Funding agency acronym MICINN
Program Programa Nacional de Proyectos de Investigación Fundamental
Subprogram Subprograma de Proyectos de Investigación Fundamental no Orientada
Call Proyectos I+D
Call year 2011
State Plan 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Management unit Subdirección General de Proyectos de Investigación
Beneficiary centre FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The blood-brain barrier: structure, function and therapeutic approaches to cross it

  • Tajes Orduña, Marta
  • Ramos Fernández, Eva, 1984-
  • Weng-Jiang, Xian
  • Bosch Morató, Mònica, 1986-
  • Guivernau Almazán, Biuse, 1988-
  • Eraso Pichot, Abel
  • Salvador, Bertrán
  • Fernàndez Busquets, Xavier
  • Roquer, Jaume
  • Muñoz López, Francisco José, 1964-
The blood-brain barrier (BBB) is constituted by a specialized vascular endothelium that interacts directly with astrocytes, neurons and pericytes. It protects the brain from the molecules of the systemic circulation but it has to be overcome for the proper treatment of brain cancer, psychiatric disorders or neurodegenerative diseases, which are dramatically increasing as the population ages. In the present work we have revised the current knowledge on the cellular structure of the BBB and the different procedures utilized currently and those proposed to cross it. Chemical modifications of the drugs, such as increasing their lipophilicity, turn them more prone to be internalized in the brain. Other mechanisms are the use of molecular tools to bind the drugs such as small immunoglobulins, liposomes or nanoparticles that will act as Trojan Horses favoring the drug delivery in brain. This fusion of the classical pharmacology with nanotechnology has opened a wide field to many different approaches with promising results to hypothesize that BBB will not be a major problem for the new generation of neuroactive drugs. The present review provides an overview of all state-of-the-art of the BBB structure and function, as well as of the classic strategies and these appeared in recent years to deliver drugs into the brain for the treatment of Central Nervous System (CNS) diseases., This work was supported by the Plan Estatal de I+D+i 2013-2016 and the ISCIII-Subdirección General de Evaluación y Fomento de la Investigación (Grants PI13/00408, PI08/00574 and Red HERACLES RD12/0042/0014 & RD12/0042/0016) and FEDER Funds; Spanish Ministry of Science and Innovation (RD12/0042/0016; BIO2011-25039); Generalitat de Catalunya (SGR09-1369 and SGR-760); and Fundació la Marató de TV3 (100310).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Posttranslational nitro-glycative modifications of albumin in Alzheimer's disease: implications in cytotoxicity and amyloid-β peptide aggregation

  • Ramos Fernández, Eva, 1984-
  • Tajes Orduña, Marta
  • Palomer, Ernest
  • Ill-Raga, Gerard, 1982-
  • Bosch Morató, Mònica, 1986-
  • Guivernau Almazán, Biuse, 1988-
  • Roman Degano, Irene
  • Eraso Pichot, Abel
  • Alcolea, Daniel
  • Fortea, Juan
  • Núñez, Laura
  • Páez, Antonio
  • Alameda Quitllet, Francisco
  • Fernàndez Busquets, Xavier
  • Lleó, Alberto
  • Elosua Llanos, Roberto
  • Boada, Mercè
  • Valverde, M. A. (Miguel Ángel), 1963-
  • Muñoz López, Francisco José, 1964-
Glycation and nitrotyrosination are pathological posttranslational modifications that make proteins prone to losing their physiological properties. Since both modifications are increased in Alzheimer's disease (AD) due to amyloid-β peptide (Aβ) accumulation, we have studied their effect on albumin, the most abundant protein in cerebrospinal fluid and blood. Brain and plasmatic levels of glycated and nitrated albumin were significantly higher in AD patients than in controls. In vitro turbidometry and electron microscopy analyses demonstrated that glycation and nitrotyrosination promote changes in albumin structure and biochemical properties. Glycated albumin was more resistant to proteolysis and less uptake by hepatoma cells occurred. Glycated albumin also reduced the osmolarity expected for a solution containing native albumin. Both glycation and nitrotyrosination turned albumin cytotoxic in a cell type-dependent manner for cerebral and vascular cells. Finally, of particular relevance to AD, these modified albumins were significantly less effective in avoiding Aβ aggregation than native albumin. In summary, nitrotyrosination and especially glycation alter albumin structural and biochemical properties, and these modifications might contribute for the progression of AD., This work was supported by the Spanish Ministry of Science and Innovation (SAF2012-38140; BIO2011-25039); Fondo de Investigación Sanitaria (PI10/00587; PI11/3035; and Red HERACLES RD06/0009, RD12/0042/0014); FEDER Funds; Generalitat de Catalunya (SGR05-266; SGR09-760); and Fundació la Marató de TV3 (100310). M.A.V. is the recipient of an ICREA Academia Award.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The blood-brain barrier: structure, function and therapeutic approaches to cross it

  • Tajes Orduña, Marta
  • Ramos Fernández, Eva, 1984-
  • Weng-Jiang, Xian
  • Bosch Morató, Mònica, 1986-
  • Guivernau Almazán, Biuse, 1988-
  • Eraso Pichot, Abel
  • Salvador, Bertrán
  • Fernàndez Busquets, Xavier
  • Roquer, Jaume
  • Muñoz López, Francisco José, 1964-
The blood-brain barrier (BBB) is constituted by a specialized vascular endothelium that interacts directly with astrocytes, neurons and pericytes. It protects the brain from the molecules of the systemic circulation but it has to be overcome for the proper treatment of brain cancer, psychiatric disorders or neurodegenerative diseases, which are dramatically increasing as the population ages. In the present work we have revised the current knowledge on the cellular structure of the BBB and the different procedures utilized currently and those proposed to cross it. Chemical modifications of the drugs, such as increasing their lipophilicity, turn them more prone to be internalized in the brain. Other mechanisms are the use of molecular tools to bind the drugs such as small immunoglobulins, liposomes or nanoparticles that will act as Trojan Horses favoring the drug delivery in brain. This fusion of the classical pharmacology with nanotechnology has opened a wide field to many different approaches with promising results to hypothesize that BBB will not be a major problem for the new generation of neuroactive drugs. The present review provides an overview of all state-of-the-art of the BBB structure and function, as well as of the classic strategies and these appeared in recent years to deliver drugs into the brain for the treatment of Central Nervous System (CNS) diseases., This work was supported by the Plan Estatal de I+D+i 2013-2016 and the ISCIII-Subdirección General de Evaluación y Fomento de la Investigación (Grants PI13/00408, PI08/00574 and Red HERACLES RD12/0042/0014 & RD12/0042/0016) and FEDER Funds; Spanish Ministry of Science and Innovation (RD12/0042/0016; BIO2011-25039); Generalitat de Catalunya (SGR09-1369 and SGR-760); and Fundació la Marató de TV3 (100310).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Posttranslational nitro-glycative modifications of albumin in Alzheimer's disease: implications in cytotoxicity and amyloid-β peptide aggregation

  • Ramos Fernández, Eva, 1984-
  • Tajes Orduña, Marta
  • Palomer, Ernest
  • Ill-Raga, Gerard, 1982-
  • Bosch Morató, Mònica, 1986-
  • Guivernau Almazán, Biuse, 1988-
  • Roman Degano, Irene
  • Eraso Pichot, Abel
  • Alcolea, Daniel
  • Fortea, Juan
  • Núñez, Laura
  • Páez, Antonio
  • Alameda Quitllet, Francisco
  • Fernàndez Busquets, Xavier
  • Lleó, Alberto
  • Elosua Llanos, Roberto
  • Boada, Mercè
  • Valverde, M. A. (Miguel Ángel), 1963-
  • Muñoz López, Francisco José, 1964-
Glycation and nitrotyrosination are pathological posttranslational modifications that make proteins prone to losing their physiological properties. Since both modifications are increased in Alzheimer's disease (AD) due to amyloid-β peptide (Aβ) accumulation, we have studied their effect on albumin, the most abundant protein in cerebrospinal fluid and blood. Brain and plasmatic levels of glycated and nitrated albumin were significantly higher in AD patients than in controls. In vitro turbidometry and electron microscopy analyses demonstrated that glycation and nitrotyrosination promote changes in albumin structure and biochemical properties. Glycated albumin was more resistant to proteolysis and less uptake by hepatoma cells occurred. Glycated albumin also reduced the osmolarity expected for a solution containing native albumin. Both glycation and nitrotyrosination turned albumin cytotoxic in a cell type-dependent manner for cerebral and vascular cells. Finally, of particular relevance to AD, these modified albumins were significantly less effective in avoiding Aβ aggregation than native albumin. In summary, nitrotyrosination and especially glycation alter albumin structural and biochemical properties, and these modifications might contribute for the progression of AD., This work was supported by the Spanish Ministry of Science and Innovation (SAF2012-38140; BIO2011-25039); Fondo de Investigación Sanitaria (PI10/00587; PI11/3035; and Red HERACLES RD06/0009, RD12/0042/0014); FEDER Funds; Generalitat de Catalunya (SGR05-266; SGR09-760); and Fundació la Marató de TV3 (100310). M.A.V. is the recipient of an ICREA Academia Award.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Possible roles of amyloids in malaria pathophysiology

  • Moles, Ernest
  • Valle Delgado, Juan José
  • Urbán, Patricia
  • Azcárate, Isabel G.
  • Bautista, José M.|||0000-0001-8926-881X
  • Selva, Javier
  • Egea, Gustavo|||0000-0001-5242-150X
  • Ventura, Salvador|||0000-0002-9652-6351
  • Fernández Busquets, Xavier|||0000-0002-4622-9631
The main therapeutic and prophylactic tools against malaria have been locked for more than a century in the classical approaches of using drugs targeting metabolic processes of the causing agent, the protist Plasmodium spp., and of designing vaccines against chosen antigens found on the parasite's surface. Given the extraordinary resources exhibited by Plasmodium to escape these traditional strategies, which have not been able to free humankind from the scourge of malaria despite much effort invested in them, new concepts have to be explored in order to advance toward eradication of the disease. In this context, amyloid-forming proteins and peptides found in the proteome of the pathogen should perhaps cease being regarded as mere anomalous molecules. Their likely functionality in the pathophysiology of Plasmodium calls for attention being paid to them as a possible Achilles' heel of malaria. Here we will give an overview of Plasmodium-encoded amyloid-forming polypeptides as potential therapeutic targets and toxic elements, particularly in relation to cerebral malaria and the blood-brain barrier function. We will also discuss the recent finding that the genome of the parasite contains an astonishingly high proportion of prionogenic domains.